In Memoriam: Professor Bernard Portmann 1940 –2018
Born in Geneva, Switzerland on 6th February 1940, Professor Bernard Portmann obtained his medical degree in 1961, before undertaking his post-graduate training in Histopathology at Geneva University, proceeding to MD in 1972 with a thesis on Hepatic Granulomas. He joined the liver unit at King ’s College Hospital in London in 1973, where he spent the rest of his career until his retirement at the end of 2009. Finally recruited by one of us, I seem to remember, over lunch at the World Health Organisation centre in Geneva, initially as a research fellow, he obtained the Royal College of P athologists membership in 1977...
Source: Journal of Hepatology - September 18, 2018 Category: Gastroenterology Authors: Roger Williams, Alberto Quaglia Tags: Obituary Source Type: research

Liver transplantation in patients with ACLF and multiple organ failure: Time for priority after initial stabilization
Short-term prognosis of cirrhotic patients with acute-on-chronic liver failure (ACLF) and multiple organ failure (MOF) is extremely poor in the absence of salvage liver transplantation (LT). Mortality correlates with the number of organ failures defined by the CLIF sequential organ failure assessment score and based on the CLIF-organ failure scoring system, reaching more than 80% at 30  days in patients with three or more organ failures even with unrestricted ICU support.1–4 The role of LT in these patients remains controversial. (Source: Journal of Hepatology)
Source: Journal of Hepatology - September 18, 2018 Category: Gastroenterology Authors: Javier Fern ández, Faouzi Saliba Tags: Editorial Source Type: research

Small molecule-mediated reprogramming of human hepatocytes into bipotent progenitor cells
Currently, liver transplantation represents the only approved standard of care for patients with end stage liver diseases.[1] Experimental studies in rodents and clinical trials of hepatocyte transplantation have shown that direct infusion of mature hepatocytes may serve as an alternative to whole organ replacement in some cases. However, hepatocyte transplantation only results in a partial and relatively short-term correction of liver dysfunction, and has been hampered by numerous issues related to the shortage of donor tissue, limited numbers of cells suitable for transplantation, and a low efficiency of engraftment in t...
Source: Journal of Hepatology - September 18, 2018 Category: Gastroenterology Authors: Yohan Kim, Kyojin Kang, Seung Bum Lee, Daekwan Seo, Sangtae Yoon, Heung Mo Yang, Sung Joo Kim, Kiseok Jang, Yun Kyung Jung, Kyeong Geun Lee, Valentina M. Factor, Jaemin Jeong, Dongho Choi Source Type: research

Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection
Worldwide, hepatocellular carcinoma (HCC) is the sixth most frequent malignancy and the second most common cause of cancer-related death.[1] There is a wide variety of therapeutic options for HCC patients, depending on tumour burden, liver function and performance status.[2] Potentially curative therapy recommended for those patients with very early/early stage tumour (Barcelona Clinic Liver Cancer [BCLC] 0/A) consists of surgical resection, liver transplantation or local ablation. Due to scarcity of donor organs, surgical resection and ablation are the mainstay of curative treatment options in Asian-Pacific countries, whi...
Source: Journal of Hepatology - September 17, 2018 Category: Gastroenterology Authors: Anthony W.H. Chan, Jianhong Zhong, Sarah Berhane, Hidenori Toyoda, Alessandro Cucchetti, KeQing Shi, Toshifumi Tada, Charing C.N. Chong, Bang-De Xiang, Le-Qun Li, Paul B.S. Lai, Vincenzo Mazzaferro, Marta Garc ía-Fiñana, Masatoshi Kudo, Takashi Kumada, Source Type: research

Multi-organ quantitative MRI for the assessment of liver disease – A whole much more than the sum of its parts
Non-invasive assessment of liver disease remains a major challenge. Ultrasound derived biomechanical measurements (FibroScan ® and shear wave elastography) are widely used because of their relatively low cost and proximity to the bedside, but sample only small areas of the liver, and thus suffer the same sampling limitations as liver biopsy. MR based methods are inherently more comprehensive, sampling the whole organ, wi th the potential to assess tissue composition using T1 mapping,1 alongside accurate quantification of liver fat (proton-density fat fraction mapping)2 and liver iron (T2∗ mapping). (Source: Journal of Hepatology)
Source: Journal of Hepatology - September 15, 2018 Category: Gastroenterology Authors: Manil D. Chouhan, Stuart A. Taylor, Rajeshwar P. Mookerjee Tags: Editorial Source Type: research

EASL-AASLD HBV endpoints, London, United Kingdom, 2019
(Source: Journal of Hepatology)
Source: Journal of Hepatology - September 14, 2018 Category: Gastroenterology Source Type: research

EASL HCC Summit 2019, Lisbon, Portugal
(Source: Journal of Hepatology)
Source: Journal of Hepatology - September 14, 2018 Category: Gastroenterology Source Type: research

Editorial Board
(Source: Journal of Hepatology)
Source: Journal of Hepatology - September 14, 2018 Category: Gastroenterology Source Type: research

EASL: Join the community or renew your membership
(Source: Journal of Hepatology)
Source: Journal of Hepatology - September 14, 2018 Category: Gastroenterology Source Type: research

EASL funding: fellowships and mentorships
(Source: Journal of Hepatology)
Source: Journal of Hepatology - September 14, 2018 Category: Gastroenterology Source Type: research

The International Liver CongressTM, Vienna, Austria, 2019
(Source: Journal of Hepatology)
Source: Journal of Hepatology - September 14, 2018 Category: Gastroenterology Source Type: research

EASL basic school: Liver cell isolation and characterisation, Dusseldorf, Germany, 2019
(Source: Journal of Hepatology)
Source: Journal of Hepatology - September 14, 2018 Category: Gastroenterology Source Type: research

Contents
(Source: Journal of Hepatology)
Source: Journal of Hepatology - September 14, 2018 Category: Gastroenterology Source Type: research

JHEP at a glance (October 2018)
(Source: Journal of Hepatology)
Source: Journal of Hepatology - September 14, 2018 Category: Gastroenterology Source Type: research

From the Editor ’s Desk…
DAAs have changed the natural history of hepatitis C virus (HCV) infection, but their impact on post-transplant outcomes is not clear. Belli et al. explored the European Liver Transplant Registry comprising over 60,000 patients, of whom 36,382 patients had HCV cirrhosis, to address this question. Their data showed a significant reduction in the percentage of patients transplanted for HCV from about 21% to about 11%. Additionally, the three-year survival of HCV cirrhosis patients undergoing orthotopic liver transplantation improved from 65.1% in the IFN/RBV era to 76.9% in the DAA era. (Source: Journal of Hepatology)
Source: Journal of Hepatology - September 14, 2018 Category: Gastroenterology Authors: Richard Moreau, Ramon Bataller, Thomas Berg, Sophie Lotersztajn, Jessica Zucman-Rossi, Rajiv Jalan Tags: Editorial Desk Source Type: research

Discover the Hepahealth Project Report
(Source: Journal of Hepatology)
Source: Journal of Hepatology - September 14, 2018 Category: Gastroenterology Source Type: research

Interspecies chimeric livers: A step closer to solving the problem of transplantable organ shortage?
‘History of medicine tells us that procedures that were inconceivable yesterday, barely achievable today often become the routine of tomorrow’.1 When Dr. Thomas E. Starzl made this remarkable statement in 1982, he knew the medical, surgical, immunological, and even political challenges to perfor ming a liver transplantation. In the 1980s, liver transplantation was a barely achievable procedure. In 2018, we are living in Dr. Starzl’s tomorrow, where the liver transplantation is a daily routine, not only in Europe2 or the United States. (Source: Journal of Hepatology)
Source: Journal of Hepatology - September 14, 2018 Category: Gastroenterology Authors: Burcin Ekser, Eric Lagasse Tags: Editorial Source Type: research

MicroRNA-378 Promotes Hepatic Inflammation and Fibrosis via Modulation of the NF κB-TNFα Pathway
The incidence of non-alcoholic fatty liver disease (NAFLD) is estimated to be 20-45% in the general population of Western countries.[1,2] Although NAFLD carries a relatively benign prognosis, a significant proportion of patients can progress to NASH and later cirrhosis with the risk of developing hepatocellular carcinoma (HCC).[3,4] It is estimated that NASH-related HCC accounts for ≥ 13% of cases in the US.[5–7] Although the progression of hepatosteatosis to NASH has been studied extensively, the precise mechanism(s) is still under intense investigation. (Source: Journal of Hepatology)
Source: Journal of Hepatology - September 12, 2018 Category: Gastroenterology Authors: Tianpeng Zhang, Junjie Hu, Xiaomei Wang, Xiaoling Zhao, Zhuoyu Li, Junqi Niu, Clifford J. Steer, Guohua Zheng, Guisheng Song Source Type: research

Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is the fifth most frequent cancer worldwide and the second cause of cancer-related deaths.[1] The vast majority of cases develop in patients with chronic liver diseases, the main risk factors being Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) infection, alcohol intake and metabolic syndrome.[2,3] Clinical outcome remains poor, with approximately only one third of patients eligible to potentially curative treatments such as surgical resection, radiofrequency ablation or liver transplantation. (Source: Journal of Hepatology)
Source: Journal of Hepatology - September 10, 2018 Category: Gastroenterology Authors: Julien Calderaro, Florent Petitprez, Etienne Becht, Alexis Laurent, Th éo Z. Hirsch, Benoit Rousseau, Alain Luciani, Giuliana Amaddeo, Jonathan Derman, Cécile Charpy, Jessica Zucman-Rossi, Wolf Herman Fridman, Catherine Sautès-Fridman Source Type: research

Claudin-3 regulates bile canalicular paracellular barrier and cholesterol gallstone cores formation in mice
Gallstone diseases have various symptoms, including pain and fever, and can lead to life-threatening conditions such as acute cholangitis, acute cholecystitis, biliary pancreatitis, and cancer of the biliary tract.[1,2] Given that gallstone diseases have a high incidence rate, are costly to treat surgically, and are responsible for lost work hours due to symptoms, preventing these diseases should have deep impacts on health and society.[1] (Source: Journal of Hepatology)
Source: Journal of Hepatology - September 10, 2018 Category: Gastroenterology Authors: Hiroo Tanaka, Mitsunobu Imasato, Yuji Yamazaki, Kengo Matsumoto, Koshi Kunimoto, Julien Delpierre, Kirstin Meyer, Marino Zerial, Naho Kitamura, Mitsuhiro Watanabe, Atsushi Tamura, Sachiko Tsukita Source Type: research

Non-invasive prediction of oesophageal varices in patients with cirrhosis secondary to non-alcoholic fatty liver disease
We read the recent cross-sectional study by Petta et al. with interest, in which they confirmed the validity of the Baveno VI and expanded Baveno VI criteria in ruling out high-risk varices (HRVs), whilst increasing the number of spared endoscopies in a cohort of patients with non-alcoholic fatty liver disease (NAFLD).1 The study also proposed the NAFLD cirrhosis criteria which discriminates between the use of medium (M) or extra-large (XL) probe. (Source: Journal of Hepatology)
Source: Journal of Hepatology - September 8, 2018 Category: Gastroenterology Authors: Jessica Shearer, David Chizhande, Rebecca Jones, Ian A Rowe Tags: Letter to the Editor Source Type: research

Corrigendum to “Alveolar echinococcosis: From a deadly disease to a well-controlled infection. Relative survival and economic analysis in Switzerland over the last 35 years” [J Hepatol 49 (2008) 72–77]
It has come to our attention that in this manuscript the name of the author ‘Nermin Halkic’ was misspelt ‘Nerman Halkik’. We apologise for this mistake and any inconvenience caused. (Source: Journal of Hepatology)
Source: Journal of Hepatology - September 8, 2018 Category: Gastroenterology Authors: Paul R. Torgerson, Alexander Schweiger, Peter Deplazes, Maja Pohar, J ürg Reichen, Rudolf W. Ammann, Philip E. Tarr, Nermin Halkic, Beat Müllhaupt Tags: Corrigendum Source Type: research

Impaired brain glymphatic flow in experimental hepatic encephalopathy
The mechanisms underlying the pathogenesis of hepatic encephalopathy (HE) in patients with cirrhosis (chronic liver disease) are not completely understood. Data available in the literature suggest that noxious substances and metabolites such as lactate, glutamate, bile acids and drugs accumulate in the brain of HE patients[1]. The currently prevailing hypothesis proposes that this occurs due to metabolic and transporter defects induced by hyperammonemia, inflammation and alterations in blood brain barrier (BBB) function [2,3]. (Source: Journal of Hepatology)
Source: Journal of Hepatology - September 7, 2018 Category: Gastroenterology Authors: Anna Hadjihambi, Ian F. Harrison, Marta Costas-Rodr íguez, Frank Vanhaecke, Natalia Arias, Rocío Gallego-Durán, Svetlana Mastitskaya, Patrick S. Hosford, Steven W.M. Olde Damink, Nathan Davies, Abeba Habtesion, Mark F. Lythgoe, Alexander V. Gourine, Ra Source Type: research

Acute-on-Chronic Liver Failure vs. Traditional Acute Decompensation of Cirrhosis
In this Grand Round presentation, the case of a woman with acute decompensation of cirrhosis due to spontaneous bacterial peritonitis is described. She subsequently developed liver failure, type 1 hepatorenal syndrome, severe hepatic encephalopathy, and respiratory failure requiring mechanical ventilation. Her critical illness raised several clinical and ethical dilemmas regarding prognosis, therapeutic options, and futility of care. We will discuss the utility of Acute-on-Chronic Liver Failure (ACLF) entity detection, the tools available for estimating outcomes, the current evidences on management of ACLF, and potential s...
Source: Journal of Hepatology - September 6, 2018 Category: Gastroenterology Authors: Thierry Gustot, Richard Moreau Tags: Grand Rounds Source Type: research

Dietary exacerbation of metabolic stress leads to accelerated hepatic carcinogenesis in glycogen storage disease type Ia
Hepatocellular carcinoma (HCC) is one of the most common primary malignancies of the liver.1 Many studies have demonstrated a strong link between hepatic tumorigenesis and non-alcoholic fatty liver diseases (NAFLDs), including obesity, diabetes and other genetic metabolic liver diseases, such as glycogen storage disease type I (GSDI).2 –4 NAFLD can go from simple steatosis characterized by hepatic fat accumulation, to the more aggressive form called non-alcoholic steatohepatitis (NASH), associated with inflammation and fibrosis. (Source: Journal of Hepatology)
Source: Journal of Hepatology - September 4, 2018 Category: Gastroenterology Authors: Monika Gjorgjieva, Julien Calderaro, Laure Monteillet, Marine Silva, Margaux Raffin, Marie Brevet, Caroline Romestaing, Damien Roussel, Jessica Zucman-Rossi, Gilles Mithieux, Fabienne Rajas Tags: Research Article Source Type: research

Reply to: “Non-invasive prediction of oesophageal varices in patients with cirrhosis secondary to non-alcoholic fatty liver disease”
In a large multicentre cohort of patients with non-alcoholic fatty liver disease (NAFLD)-related compensated cirrhosis, we recently confirmed that expanded Baveno VI works better than Baveno VI criteria for ruling-out the presence of varices needing treatment (VNT).1 We also elaborated new, more accurate criteria – named NAFLD cirrhosis criteria – optimized for M and XL FibroScan probes, and always based on liver stiffness measurement and platelet values, which were able to spare more than 50% of unnecessary esophagogastroduodenoscopy (EGD). (Source: Journal of Hepatology)
Source: Journal of Hepatology - September 4, 2018 Category: Gastroenterology Authors: Salvatore Petta, Giada Sebastiani, Victor de Ledinghen Tags: Letter to the Editor Source Type: research

Primary biliary cholangitis: a tale of epigenetically-induced secretory failure?
Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease associated with autoimmune phenomena targeting small to medium size intrahepatic bile ducts. The aetiology of PBC is unknown and its pathogenesis remains obscure. Both genetic variants and environmental factors have been linked to increased PBC susceptibility, although other alterations also cooperate in disease pathobiology. Increasing evidence indicates the presence of epigenetic abnormalities in PBC, particularly alterations of cholangiocellular microRNAs (miRNAs or miRs). (Source: Journal of Hepatology)
Source: Journal of Hepatology - September 4, 2018 Category: Gastroenterology Authors: Pedro M. Rodrigues, Maria J. Perugorria, Alvaro Santos-Laso, Luis Bujanda, Ulrich Beuers, Jesus M. Banales Tags: Review Source Type: research

Antiviral therapy in hepatitis B virus-infected immunotolerant children, exploring a new land
I have read with great interest the article presented by Zhu et al. titled “Antiviral therapy in hepatitis B virus-infected children with immune-tolerant characteristics: A pilot open-label randomized study” published in Journal of Hepatology in June 2018. 1 The study explores an important area of HBV yet to be fully explored, and has stretched restrictive boundaries p roposed by treatment guidelines, as the American Association for the Study of Liver Diseases suggested antiviral therapy in HBV e antigen positive children (ages 2 to (Source: Journal of Hepatology)
Source: Journal of Hepatology - August 31, 2018 Category: Gastroenterology Authors: Mohamed Aly Mokhles Tags: Letter to the Editor Source Type: research

Reply to: “Antiviral therapy in hepatitis B virus-infected immunotolerant children, exploring a new land”
I sincerely welcome the thoughtful letter from Professor Mohamed Aly Mokhles. The quotation from Pink Floyd impresses me deeply. Herein, I have the opportunity to continue the meaningful discourse. The following is my reply to the letter. (Source: Journal of Hepatology)
Source: Journal of Hepatology - August 30, 2018 Category: Gastroenterology Authors: Pan Zhao Tags: Letter to the Editor Source Type: research

Reply to: “Prevalent acute-on-chronic liver failure and response to corticosteroids in alcoholic hepatitis”
We read with interest the letter by Forrest et al. [1], wherein they evaluate the survival analysis of patients with severe alcoholic hepatitis (sAH) and acute-on-chronic liver failure (ACLF) from the STOPAH study [2]. (Source: Journal of Hepatology)
Source: Journal of Hepatology - August 29, 2018 Category: Gastroenterology Authors: Thomas Serst é, Christophe Moreno, Thierry Gustot Tags: Letter to the Editor Source Type: research

Corrigendum to “EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis” [J Hepatol 69 (2018) 406–460]
It has come to our attention that there is an error in the original manuscript in the section entitled ‘Renal impairment’ on page 429. The sentence ‘Recent studies have suggested that in patients with cirrhosis, in AKI stage 1, SCr (Source: Journal of Hepatology)
Source: Journal of Hepatology - August 29, 2018 Category: Gastroenterology Authors: European Association for the Study of the Liver Tags: Corrigendum Source Type: research

Immune and Metabolic Shifts During Neonatal Development Reprogram Liver Identity and Function
The liver has multiple functions and its vital importance starts during gestational phase [1]. The primordial liver is formed in the initial stages of embryonic development (week 4 in humans and E8.5 in mouse), and it is the destination of several immune cell precursors that arise from the yolk sac [2]. Fetal liver harbors different hepatic progenitor cells and a great number of other mesenchyme-derived cells, including immune cells in different stages of maturation [3]. In fact, macrophages, hematopoietic stem cells (HSCs), endothelial and mesenchymal stem cells compose a complex cellular repertoire during the major part ...
Source: Journal of Hepatology - August 29, 2018 Category: Gastroenterology Authors: Brenda Naemi Nakagaki, Kassiana Mafra, Érika de Carvalho, Mateus Eustáquio Lopes, Raquel Carvalho-Gontijo, Hortência Maciel de Castro Oliveira, Gabriel Henrique Campolina-Silva, Camila Dutra Moreira de Miranda, Maísa Mota Antunes, Ana Carolina Carvalh Source Type: research

Prevalent acute-on-chronic liver failure and response to corticosteroids in alcoholic hepatitis
We read the paper by Serst é et al. regarding the significance of acute-on-chronic liver failure (ACLF) in alcoholic hepatitis (AH) with interest.1 They conclude that ACLF in AH is associated with a poor outcome and that the Lille response to corticosteroids was reduced in those with prevalent ACLF. (Source: Journal of Hepatology)
Source: Journal of Hepatology - August 24, 2018 Category: Gastroenterology Authors: Ewan H. Forrest, Stephen R. Atkinson, Paul Richardson, Steven Masson, Stephen Ryder, Mark R. Thursz, Michael Allison, the STOPAH Trial Management Group Tags: Letter to the Editor Source Type: research

EASL Clinical Practice Guidelines on nutrition in chronic liver disease
A frequent complication in liver cirrhosis is malnutrition, which is associated with the progression of liver failure, and with a higher rate of complications including infections, hepatic encephalopathy and ascites. In recent years, the rising prevalence of obesity has led to an increase in the number of cirrhosis cases related to non-alcoholic steatohepatitis. Malnutrition, obesity and sarcopenic obesity may worsen the prognosis of patients with liver cirrhosis and lower their survival. Nutritional monitoring and intervention is therefore crucial in chronic liver disease. (Source: Journal of Hepatology)
Source: Journal of Hepatology - August 22, 2018 Category: Gastroenterology Authors: European Association for the Study of the Liver Tags: Clinical Practice Guidelines Source Type: research

The Conundrum of Cryptogenic Cirrhosis: Adverse Outcomes without Treatment Options
Survival free of clinical disease progression in patients with cryptogenic cirrhosis and NASH cirrhosis (Source: Journal of Hepatology)
Source: Journal of Hepatology - August 22, 2018 Category: Gastroenterology Authors: Zobair Younossi, Maria Stepanova, Arun J. Sanyal, Stephen A. Harrison, Vlad Ratziu, Manal F. Abdelmalek, Anna Mae Diehl, Stephen Caldwell, Mitchell L. Shiffman, Raul Aguilar Schall, Bryan McColgan, G. Mani Subramanian, Robert P. Myers, Andrew Muir, Nezam Source Type: research

Inactivation of Caspase 8 in liver parenchymal cells confers protection against murine obstructive cholestasis
Cholestasis refers to a decrease in bile flow due to impaired secretion by hepatocytes or obstruction of the intra- or extrahepatic bile ducts. In humans, the most prominent disease is biliary obstruction of the common bile duct by gallstones. Other diseases include primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC) or biliary atresia (BA). Experimental surgical ligation of the common bile duct (BDL) is the standard experimental model of obstructive cholestatic injury [1]. BDL causes complete biliary obstruction and accumulation of toxic bile acids in liver and serum as observed in patients. (Source: J...
Source: Journal of Hepatology - August 22, 2018 Category: Gastroenterology Authors: Francisco Javier Cubero, Jin Peng, Lijun Liao, Huan Su, Gang Zhao, Miguel Eugenio Zoubek, Ricardo Macias-Rodriguez, Astrid Ruiz-Margain, Johanna Rei ßing, Henning W. Zimmermann, Nikolaus Gassler, Tom Luedde, Christian Liedtke, Maximilian Hatting, Christi Source Type: research

Corrigendum to “From the Editor’s Desk August 2018” [J Hepatol 69 (2018) 265–268]
It has come to our attention that when citing the paper by Ferriero et al. the author ’s name was misspelt ‘Ferreiro’ in the text and the figure caption. Please note that the correct name for this author is ‘Ferriero’. In the figure cited for this paper the arrow between Pyruvate and Acetyl-coA should be pointing from Pyruvate to Acetyl-coA, as in the original paper. We apo logise for these errors which have now been corrected in the online version of this manuscript. (Source: Journal of Hepatology)
Source: Journal of Hepatology - August 22, 2018 Category: Gastroenterology Authors: Richard Moreau, Ramon Bataller, Thomas Berg, Sophie Lotersztajn, Jessica Zucman-Rossi, Rajiv Jalan Tags: Corrigendum Source Type: research

Hepatitis C Virus Reinfection after Successful Treatment with Direct-Acting Antiviral Therapy in a Large Population-Based Cohort
Chronic hepatitis C virus (HCV) is associated with substantial morbidity and mortality, with> 71 million people infected worldwide in 2015 [1]. In 2013, an estimated 700,000 deaths globally were attributed to HCV-related liver disease sequelae, namely cirrhosis and hepatocellular carcinoma [2]. Mortality is expected to increase as many individuals infected with HCV decades ago are aging and at high risk of chronic liver disease [3,4]. With the introduction of highly effective and well-tolerated, all-oral direct-acting antiviral (DAA) therapies to treat chronic HCV infection[5,6], there has been renewed optimism regardin...
Source: Journal of Hepatology - August 22, 2018 Category: Gastroenterology Authors: Carmine Rossi, Zahid Butt, Stanley Wong, Jane Buxton, Nazrul Islam, Amanda Yu, Maryam Darvishian, Mark Gilbert, Jason Wong, Nuria Chapinal, Mawuena Binka, Maria Alvarez, Mark Tyndall, Mel Krajden, Naveed Janjua, The BC Hepatitis Testers Cohort Team Source Type: research

miRNAs in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis
Non-alcoholic fatty liver disease (NAFLD) is characterized by excessive fat accumulation without a history of excessive alcohol intake, and the absence of other known liver diseases, such as hepatitis B and hepatitis C virus infection.[1 –3] NAFLD has been described as the hepatic manifestation of metabolic syndrome, associated with insulin resistance and genetic susceptibility. NAFLD affects 30% to 40% of the United States population[4], 2% to 44% of the European population[5], and 15% to 45% of the Asian population[6], while the Hispanic population is the most susceptible, as up to 45% of this population suffers fr...
Source: Journal of Hepatology - August 22, 2018 Category: Gastroenterology Authors: Chang-Hai Liu, Javier Ampuero, Antonio Gil-G ómez, Rocío Montero-Vallejo, Ángela Rojas, Rocío Muñoz-Hernández, Rocío Gallego-Durán, Manuel Romero-Gómez Source Type: research

Beneficial Effects of Lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease (NAFLD) is currently the most common chronic liver disease and is one of the leading causes of end-stage liver disease and hepatocellular carcinoma worldwide [1,2]. Although NAFLD is strongly associated with metabolic syndrome and obesity [3], around 10-20% of NAFLD patients have relatively normal body mass index (BMI), a condition often described as non-obese or lean NAFLD [4]. Studies based on liver histology or non-invasive tests of fibrosis suggest that these non-obese patients may also harbor non-alcoholic steatohepatitis (NASH) and advanced fibrosis [5 –8]. (Source: Journal of Hepatology)
Source: Journal of Hepatology - August 22, 2018 Category: Gastroenterology Authors: Vincent Wai-Sun Wong, Grace Lai-Hung Wong, Ruth Suk-Mei Chan, Sally She-Ting Shu, Bernice Ho-Ki Cheung, Liz Sin Li, Angel Mei-Ling Chim, Carmen Ka-Man Chan, Julie Ka-Yu Leung, Winnie Chiu-Wing Chu, Jean Woo, Henry Lik-Yuen Chan Source Type: research

Hepatitis B virus (HBV) genome recycling and de novo secondary infection events maintain stable cccDNA levels
Hepatitis B virus (HBV) chronically infects 257 million individuals worldwide and is a major driver of end-stage liver diseases such as cirrhosis and hepatocellular carcinoma [WHO 2017]. The immense death toll of 887,000 individuals/year drives an intensive search for curative treatment approaches. However, a more detailed understanding of infection kinetics and the genesis and maintenance of episomal nuclear DNA pools, so called covalently closed circular (ccc) DNA, is needed to guide the development of an HBV cure. (Source: Journal of Hepatology)
Source: Journal of Hepatology - August 22, 2018 Category: Gastroenterology Authors: Chunkyu Ko, Anindita Chakraborty, Wen-Min Chou, Julia Hasreiter, Jochen M. Wettengel, Daniela Stadler, Romina Bester, Theresa Asen, Ke Zhang, Karin Wisskirchen, Jane A. McKeating, Wang-Shick Ryu, Ulrike Protzer Source Type: research

The role of HLA-A*33:01 in patients with cholestatic hepatitis attributed to terbinafine
Terbinafine is an orally administered antifungal agent that is commonly used to treat superficial fungal infections of the skin and nails. It was approved for use in the United States in 1998 and is typically given in an oral dose of 250  mg daily for 6 to 12 weeks. Terbinafine use is associated with mild liver biochemistry abnormalities in (Source: Journal of Hepatology)
Source: Journal of Hepatology - August 20, 2018 Category: Gastroenterology Authors: Robert John Fontana, Elizabeth Theresa Cirulli, Jiezhun Gu, David Kleiner, David Ostrov, Elizabeth Phillips, Ryan Schutte, Huiman Barnhart, Naga Chalasani, Paul Brent Watkins, Jay H. Hoofnagle Tags: Research Article Source Type: research

The role of HLA-A ∗33:01 in Patients with Cholestatic Hepatitis attributed to Terbinafine
Example: A ribbon diagram demonstrating docking of a terbinafine molecule in the protein binding cleft of HLA-A ∗ 33:01 (blue), HLA-B ∗ 14:02 (green), and HLA-C ∗ 08:02 locus. (Source: Journal of Hepatology)
Source: Journal of Hepatology - August 20, 2018 Category: Gastroenterology Authors: Robert John Fontana, Elizabeth Theresa Cirulli, Jiezhun Gu, David Kleiner, David Ostrov, Elizabeth Phillips, Ryan Schutte, Huiman Barnhart, Naga Chalasani, Paul Brent Watkins, Jay H. Hoofnagle Source Type: research

Clinical and Histologic Features of Adults with Alpha-1 Antitrypsin Deficiency in a Non-Cirrhotic Cohort
Alpha-1 antitrypsin deficiency (AATD) is an inherited cause of liver disease in adults and children. The underlying genetic change is a point mutation in the serine protease inhibitor alpha-1-antitrypsin.[1] In the classic form of AATD, affected individuals are homozygous for the Z allele (ZZ), where a Glu342Lys substitution leads to a misfolded protein. The resulting protein conformation (ATZ) favors retention and subsequent polymerization within the hepatocyte endoplasmic reticulum (ER).[2] These polymers form the PAS-positive inclusions that are the hallmark of AATD liver disease on biopsy. (Source: Journal of Hepatology)
Source: Journal of Hepatology - August 20, 2018 Category: Gastroenterology Authors: Virginia C. Clark, George Marek, Chen Liu, Amy Collinsworth, Jonathan Shuster, Tracie Kurtz, Joanna Nolte, Mark Brantly Source Type: research

MIDODRINE & ALBUMIN for Preventing COMPLICATIONS IN PATIENTS WITH CIRRHOSIS AWAITING Liver transplantation
Natural history of decompensated cirrhosis is characterized by the development of recurrent complications of the disease, leading to frequent hospital admissions, impaired quality of life and increased mortality [1 –5]. Liver transplantation (LT) is the definitive treatment for patients with end-stage liver disease. Patients with decompensated cirrhosis present good outcomes after LT with 3-year survival above 80% [5–8]. However, one of the major concerns is the development of complications while on the wa iting list, which may be a cause of death or may delay or preclude patients with decompensated cirrhosis f...
Source: Journal of Hepatology - August 20, 2018 Category: Gastroenterology Authors: Elsa Sol à, Cristina Solé, Macarena Simón-Talero, Marta Martín-Llahí, José Castellote, Rita Garcia-Martínez, Rebeca Moreira, Maria Torrens, Francisca Márquez, Núria Fabrellas, Gloria de Prada, Patrícia Huelin, Eva Lopez Benaiges, Meritxell Ventu Source Type: research

Pregnancy in Idiopathic Non-Cirrhotic Portal Hypertension: A Multicentric Study on Maternal and Fetal Management and Outcome
Idiopathic portal hypertension, non-cirrhotic portal fibrosis and idiopathic non-cirrhotic portal hypertension (INCPH) indicate the same clinical entity.[1] These terms, thereafter referred to as INCPH, designate a heterogeneous group of liver diseases causing portal hypertension and characterized by the absence of cirrhotic modification of the liver parenchyma and the patency of the portal and hepatic veins. Liver histological lesions found in patients with INCPH include obliterative portal venopathy, hepatoportal sclerosis, nodular regenerative hyperplasia and incomplete septal cirrhosis. (Source: Journal of Hepatology)
Source: Journal of Hepatology - August 20, 2018 Category: Gastroenterology Authors: Filipe Andrade, Akash Shukla, Christophe Bureau, Marco Senzolo, Louis D'Alteroche, Alexandra Heurgu é, Juan-Carlos Garcia-Pagan, Fanny Turon, Frédéric Oberti, Dhiraj Tripathi, Olivier Roux, Pierre-François Ceccaldi, Emmanuelle de Raucourt, Audrey Paya Source Type: research

Development of Models Estimating the Risk of Hepatocellular Carcinoma After Antiviral Treatment for Hepatitis C
Most patients with chronic hepatitis C virus (HCV) infection have either already received antiviral treatment or are expected to receive treatment with direct-acting antivirals (DAAs) in the next 3-5 years in the United States. With sustained virologic response (SVR) rates well in excess of 90%, the vast majority of treated patients will achieve HCV eradication. SVR reduces hepatocellular carcinoma (HCC) risk substantially, irrespective of whether it is achieved by interferon (IFN) or DAA-based regimens[1]. (Source: Journal of Hepatology)
Source: Journal of Hepatology - August 20, 2018 Category: Gastroenterology Authors: George N. Ioannou, Pamela K. Green, Lauren A. Beste, Elijah J. Mun, Kathleen F. Kerr, Kristin Berry Source Type: research

Discover the Hepahealth Project Report
(Source: Journal of Hepatology)
Source: Journal of Hepatology - August 15, 2018 Category: Gastroenterology Source Type: research

Editorial Board
(Source: Journal of Hepatology)
Source: Journal of Hepatology - August 15, 2018 Category: Gastroenterology Source Type: research

EASL basic school: Liver cell isolation and characterisation, Dusseldorf, Germany, 2019
(Source: Journal of Hepatology)
Source: Journal of Hepatology - August 15, 2018 Category: Gastroenterology Source Type: research